China National Biotec Group Company Limited

China National Biotec Group (CNBG) is a China-based state-owned biologics and vaccine manufacturer headquartered in Beijing. Founded in 1919, it is a subsidiary of Sinopharm. The group operates 7 human vaccine bases, 2 animal vaccine bases, and controls 85 plasma stations nationwide, employing over 10,000 manufacturing personnel. CNBG is the world's fourth-largest vaccine manufacturer by output.

Business Overview

CNBG serves as the industrial backbone of China's public health infrastructure. The group produces over 200 biomedicine products across nearly 100 GMP-certified production lines. Its vaccine portfolio spans 34 types covering 26 viruses and bacteria, with an annual distribution capacity exceeding 8 billion doses. Through its listed subsidiary Tiantan Biological Products (SSE: 600161), CNBG operates China's largest plasma collection network — 85 licensed stations that collected 2,801 tons of plasma in 2025.

The group's six subordinate research institutes (Beijing, Changchun, Chengdu, Lanzhou, Shanghai, Wuhan) combine R&D with manufacturing under a single organizational roof. CNBG fulfilled over 80% of China's national immunization programme vaccine assignments in 2025, making it the single most critical supplier to the world's largest public health system. The group also exports vaccines to developing countries through WHO prequalification and bilateral aid agreements.

Key Strengths

1. Unmatched manufacturing scale with nearly 100 GMP production lines and 7 major human vaccine bases spanning six provincial cities. 2. Deep vertical integration from plasma collection through purification to sterile fill-finish — entirely within proprietary facilities. 3. Government-backed procurement guarantees, with over 80% of national immunization programme production assignments, ensuring stable baseline revenue. 4. World-class R&D team including an Academician of the Chinese Academy of Engineering and over 170 experts receiving national government allowances. 5. Largest domestic plasma collection network (85 stations, 2,801 tons/year) providing critical upstream raw material security.

Challenges & Outlook

CNBG faces significant domestic pricing headwinds. Its listed subsidiary Tiantan Biological saw net profit decline 29.59% year-over-year in 2025 to RMB 1.091 billion, reflecting severe price erosion in China's volume-based procurement environment. The group's international revenue diversification remains limited, with the vast majority of sales concentrated in the Chinese market and developing-country aid programs. State-owned governance structures create bureaucratic friction that has already cost the group strategic M&A opportunities — notably the abandoned acquisition of rival Pailin Bio in 2025. Future growth will depend on successful commercialization of next-generation vaccines, deeper international market penetration, and operational efficiency improvements to offset domestic margin compression.